Skip to the page

Data / Drug companies / Ani Pharmaceuticals, Inc.

Ani Pharmaceuticals, Inc.: 145 products in the FDA NDC directory, labeler code 62559

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Ani Pharmaceuticals, Inc. (labeler code 62559) lists 145 products in the FDA National Drug Code Directory, covering 57 finished drugs by generic name. By type: 144 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 27, 2026.

The request: Watch Ani Pharmaceuticals, Inc. (FDA labeler code 62559): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
62559
Products in commercial distribution
145
Packages
196
Finished drugs by generic name
57
Prescription products
144
Over the counter products
1
Controlled substance products
Schedule II 3, Schedule III 2, Schedule IV 3, Schedule V 1
Flagged as original packager
142 of 142 products that carry the flag
Started marketing in the last 12 months
9
Products with a marketing end date set
2
Earliest marketing start
December 22, 2010
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)7551.7%
New drug applications (NDA)3020.7%
Authorized generics (NDA)2819.3%
Other unapproved drugs128.3%

Products by type

TypeProductsShare
Prescription drugs14499.3%
Over the counter drugs10.7%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet6846.9%
Capsule1812.4%
Capsule, extended release1611%
Tablet, coated64.1%
Solution64.1%
Tablet, film coated64.1%
Cream42.8%
Tablet, extended release32.1%
Enema32.1%
Granule, for suspension32.1%
Injection32.1%
Powder, for solution21.4%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Benazepril Hydrochloride62559-527TabletGeneric drugs (ANDA)July 27, 2026
Benazepril Hydrochloride62559-526TabletGeneric drugs (ANDA)July 27, 2026
Benazepril Hydrochloride62559-525TabletGeneric drugs (ANDA)July 27, 2026
Benazepril Hydrochloride62559-524TabletGeneric drugs (ANDA)July 27, 2026
Carbamazepine62559-486Capsule, extended releaseGeneric drugs (ANDA)April 13, 2026
Carbamazepine62559-485Capsule, extended releaseGeneric drugs (ANDA)April 13, 2026
Carbamazepine62559-484Capsule, extended releaseGeneric drugs (ANDA)April 13, 2026
Isosorbide Mononitrate62559-253TabletGeneric drugs (ANDA)March 27, 2026
Isosorbide Mononitrate62559-252TabletGeneric drugs (ANDA)March 27, 2026
Risperidone62559-981SolutionGeneric drugs (ANDA)October 27, 2025
Oxcarbazepine62559-222Tablet, film coatedGeneric drugs (ANDA)July 15, 2025
Oxcarbazepine62559-221Tablet, film coatedGeneric drugs (ANDA)July 15, 2025
Oxcarbazepine62559-220Tablet, film coatedGeneric drugs (ANDA)July 15, 2025
Purified Cortrophin Gel62559-861InjectionNew drug applications (NDA)February 28, 2025
Memantine and donepezil hydrochlorides62559-207Capsule, extended releaseGeneric drugs (ANDA)January 1, 2025
Carboprost Tromethamine62559-900InjectionGeneric drugs (ANDA)December 20, 2024
Lorazepam62559-197TabletGeneric drugs (ANDA)December 1, 2024
Lorazepam62559-196TabletGeneric drugs (ANDA)December 1, 2024
Lorazepam62559-195TabletGeneric drugs (ANDA)December 1, 2024
Promethazine Hydrochloride and Dextromethorphan Hydrobromide62559-758SolutionAuthorized generics (NDA)September 5, 2024
Fluocinolone acetonide62559-289CreamAuthorized generics (NDA)May 8, 2024
Fluocinolone acetonide62559-288CreamAuthorized generics (NDA)May 8, 2024
Kionex62559-356SuspensionGeneric drugs (ANDA)May 3, 2024
Baclofen62559-204SuspensionGeneric drugs (ANDA)March 18, 2024
Candesartan cilexetil62559-689TabletAuthorized generics (NDA)March 15, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.